Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We conducted a randomized trial of the treatment of multiple myeloma with high-dose chemotherapy followed by either one or two successive autologous stem-cell transplantations. METHODS: At the time of diagnosis, 399 previously untreated patients under the age of 60 years were randomly assigned to receive a single or double transplant. RESULTS: A complete or a very good partial response was achieved by 42 percent of patients in the single-transplant group and 50 percent of patients in the double-transplant group (P=0.10). The probability of surviving event-free for seven years after the diagnosis was 10 percent in the single-transplant group and 20 percent in the double-transplant group (P=0.03). The estimated overall seven-year survival rate was 21 percent in the single-transplant group and 42 percent in the double-transplant group (P=0.01). Among patients who did not have a very good partial response within three months after one transplantation, the probability of surviving seven years was 11 percent in the single-transplant group and 43 percent in the double-transplant group (P<0.001). Four factors were significantly related to survival: base-line serum levels of beta2-microglobulin (P<0.01) and lactate dehydrogenase (P<0.01), age (P<0.05), and treatment group (P<0.01). CONCLUSIONS: As compared with a single autologous stem-cell transplantation after high-dose chemotherapy, double transplantation improves overall survival among patients with myeloma, especially those who do not have a very good partial response after undergoing one transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In earlier randomized trials, an improvement in OS was seen in two studies,132,133 but other studies failed to show such an improvement.134,135”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [132]
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Self-citationHigh-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Moreau, P. (2002) · Blood · doi:10.1182/blood.v99.3.731 · Cited by 564
Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55 · Cited by 472
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3832 · Cited by 433
INTENSIVE TREATMENT OF MULTIPLE MYELOMA AND CRITERIA FOR COMPLETE REMISSION
Gore, M. E., Viner, C., Meldrum, M., Bell, J., Milan, S., Zuiable, A., Slevin, M., Selby, P. J., Clark, P. I., Millar, B., et al. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91548-1 · Cited by 190
Research works printed but not linked: 7
- Barlogie B, 1991, Bone Marrow Transplant, 7, 71
- Fermand J-P, 1999, Blood, 94, 396a
- Blade J, 2001, Blood, 98, 815a
- Palumbo A, 2001, Blood, 98, 849a
- Fermand J-P, 2001, Blood, 98, 815a
- Richardson P, 2002, Blood, 100, 104a
- Sirohi B, 2002, Bone Marrow Transplant, 29, S12
Cited by
Items 101–200 of 987
Role of stem cells in cancer therapy and cancer stem cells: a review
Sagar, J., Chaib, B., Sales, K. M., Winslet, M. C., & Seifalian, A. M. (2007) · Cancer Cell International · doi:10.1186/1475-2867-7-9 · Cited by 165
Sung, B., Kunnumakkara, A. B., Sethi, G., Anand, P., Guha, S., & Aggarwal, B. B. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0905 · Cited by 159
Richardson, P. G. G., Mitsiades, C. S., Laubach, J. P., Lonial, S., Chanan-Khan, A. A., & Anderson, K. C. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08360.x · Cited by 157
Lacy, M. Q., Gertz, M. A., Dispenzieri, A. A., Hayman, S. R., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S. K., Greipp, P. R., Fonseca, R., et al. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.10.1179 · Cited by 151
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
Treon, S. P., Branagan, A. R., Ioakimidis, L., Soumerai, J. D., Patterson, C. J., Turnbull, B. A., Wasi, P., Emmanouilides, C. E., Frankel, S. R., Lister, A. T., et al. (2008) · Blood · doi:10.1182/blood-2008-09-177329 · Cited by 153
Approach to the treatment of multiple myeloma: a clash of philosophies
Rajkumar, S. V., Gahrton, G., & Bergsagel, P. L. (2011) · Blood · doi:10.1182/blood-2011-06-297853 · Cited by 137
Barlogie, B., Tricot, G. J. K., Rasmussen, E., Anaissie, E. J., van Rhee, F., Zangari, M., Fassas, A., Hollmig, K. A., Pineda‐Roman, M., Shaughnessy, J. D., et al. (2005) · Blood · doi:10.1182/blood-2005-10-4084 · Cited by 141
“Total therapy 1 Enrollment 231 100 0 0 0 0 None NA NA Induction 231 100 8 6 8 (6) 14 None 145 (63) 27 (12) First transplantation 195 84 9 9 2 (2) 10 None 175 (76) 60 (26) Second transplantation 165 71 16 2 6 (3) 13 None 188 (81) 84 (36) Maintenance 128 55 0 83 15 (2) 21 None 189 (82) 94 (41) Total therapy 2, no thalid…”
Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back
Bianchi, G., & Anderson, K. C. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21252 · Cited by 131
Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?
Bahlis, N. J., & Lazarus, H. M. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705395 · Cited by 144
How I treat multiple myeloma in younger patients
Stewart, A. K., Richardson, P. G., & San-Miguel, J. F. (2009) · Blood · doi:10.1182/blood-2009-07-204651 · Cited by 133
Current Trends in Autologous Stem-Cell Transplantation for Myeloma in the Era of Novel Therapies
Moreau, P., Avet-Loiseau, H., Harousseau, J.-L., & Attal, M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.5878 · Cited by 132
“ASCT.38 The second novel agent to become available, bortezomib, was investigated in combination with dexamethasone in a large trial conducted by the IFM and prospectively compared with VAD for both efficacy and safety in previously untreated MM patients (Table 3).”
MethodSelf-citationDurie, B. G. M., Jacobson, J. L., Barlogie, B., & Crowley, J. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.111 · Cited by 132
Hematopoietic stem cell transplantation for multiple myeloma beyond 2010
Bladé, J., Rosiñol, L., Cibeira, M. T., Rovira, M., & Carreras, E. (2010) · Blood · doi:10.1182/blood-2009-08-238196 · Cited by 138
“The IFM group reported that the median survival was prolonged by 10 months with tandem transplant and that the OS at 7 years of follow-up for tandem and single ASCT were 42% and 21%, respectively (28).”
BackgroundRifkin, R. M., Gregory, S. A., Mohrbacher, A. M., & Hussein, M. A. (2006) · Cancer · doi:10.1002/cncr.21662 · Cited by 136
“Although rapid response and relief of symptoms for patients with multiple myeloma are desirable, the quality of response to nonmyeloablative doses of chemotherapy does not appear to correlate with improvements in survival for patients with multiple myeloma, as opposed to transplantation approaches.(7,21,22) In contras…”
BackgroundCompromised stem cell mobilization following induction therapy with lenalidomide in myeloma
Paripati, H. R., Stewart, A. K., Cabou, S., Dueck, A. C., Zepeda, V. J. J., Pirooz, N. A., Ehlenbeck, C., Reeder, C. B., Slack, J. L., Leis, J. F., et al. (2008) · Leukemia · doi:10.1038/sj.leu.2405100 · Cited by 136
Shah, N., Callander, N. S., Ganguly, S., Gul, Z., Hamadani, M., Costa, L. J., Sengsayadeth, S. M., Abidi, M. H., Hari, P., Mohty, M., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.03.002 · Cited by 140
“The landmark IFM trial demonstrated a benefit from the tandem auto-HCT in all parameters: EFS, relapse-free survival (RFS), and OS [46].”
BackgroundMethodGay, F., Engelhardt, M. M., Terpos, E., Wäsch, R., Giaccone, L., Auner, H. W., Caers, J., Gramatzki, M., van de Donk, N. W. C. J., Oliva, S., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.174573 · Cited by 133
Abdelkefi, A., Ladeb, S., Torjman, L., Othman, T. B., Lakhal, A., Romdhane, N. B., Omri, H. E., Elloumi, M., Bellâaj, H., Jeddi, R., et al. (2007) · Blood · doi:10.1182/blood-2007-07-101212 · Cited by 127
“thrombocytopenia,† days (range) 9 (2-19) 10 (2-20) NS”
BackgroundInfluentialRetractedMoreau, P., Attal, M., Pégourié, B., Planche, L., Hulin, C., Facon, T., Stoppa, A.-M., Fuzibet, J.-G., Grosbois, B., Doyen, C., et al. (2011) · Blood · doi:10.1182/blood-2010-08-300863 · Cited by 123
Self-citationBarlogie, B., Anaissie, E., Haessler, J., van Rhee, F., Pineda‐Roman, M., Hollmig, K., Alsayed, Y., Epstein, J., Shaughnessy, J. D., & Crowley, J. (2008) · Cancer · doi:10.1002/cncr.23546 · Cited by 121
“Thus, raising CR frequency from less than 5% with standard melphalan-prednisone toward 50% with high-dose melphalan-based transplants was associated with an extension of median survival from less than 3 years to beyond 5 years.(4,5) For the reasons cited earlier, however, it is now apparent that CR per se is not a gua…”
BackgroundGonsalves, W. I., Buadi, F. K., Ailawadhi, S., Bergsagel, P. L., Khan, A. A. C., Dingli, D., Dispenzieri, A. A., Fonseca, R., Hayman, S. R., Kapoor, P., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0264-8 · Cited by 130
Mark, T., Stern, J., Furst, J. R., Jayabalan, D., Zafar, F., LaRow, A., Pearse, R. N., Harpel, J., Shore, T., Schuster, M. W., et al. (2008) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2008.04.008 · Cited by 117
“In addition, the goal for the absolute number of stem cells to be collected has increased because of studies reporting a survival benefit with tandem ASCT, as well as the potential use of high-dose chemotherapy with stem cell rescue as salvage therapy [1,3-5].”
BackgroundEBMT activity survey 2004 and changes in disease indication over the past 15 years
Gratwohl, A. A., Baldomero, H., Frauendorfer, K., & Urbano-Ispizúa, Á. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705377 · Cited by 125
Costa, L. J., Zhang, M., Zhong, X., Dispenzieri, A. A., Lonial, S., Krishnan, A. Y., Freytes, C. O., Vesole, D. H., Gale, R. P., Anderson, K. C., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.08.002 · Cited by 114
“001 No 224 (33) 469 (32) 914 (41) Missing 21 (3) 59 (4) 334 (15) Treatment-related Lines of chemotherapy prior to transplant 1 477 (70) 921 (63) 1410 (63) <0.”
BackgroundStiff, P. J., Micallef, I. N., McCarthy, P. L., Magalhaes-Silverman, M. D., Weisdorf, D. J., Territo, M., Badel, K., & Calandra, G. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.11.028 · Cited by 113
“Heavily pretreated patients were defined as those who had received 10 or more total cycles of chemotherapy, had received platinum-based chemotherapy either at diagnosis or at the time of relapse, or had received any dose of radiation to bone marrow bearing sites, these patients have historically been poor mobilizers […”
BackgroundMethodSalvage Second Hematopoietic Cell Transplantation in Myeloma
Michaelis, L. C., Saad, A. A., Zhong, X., Le‐Rademacher, J. G., Freytes, C. O., Marks, D. I., Lazarus, H. M., Bird, J. M., Holmberg, L., Kamble, R. T., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.01.004 · Cited by 110
“ACHT2 is a distinct treatment strategy compared with tandem AHCT, which is defined as two planned cycles of high-dose therapy with peripheral blood progenitor cell support in which a second AHCT is performed within 180 days of the first, with the objective of increasing the likelihood of a complete or very good partia…”
ResultNitz, U. A., Mohrmann, S., Fischer, J., Lindemann, W., Berdel, W. E., Jackisch, C., Werner, C., Ziske, C. G., Kirchner, H. H., Metzner, B., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67784-7 · Cited by 108
Hussein, M. A., Baz, R., Srkalović, G., Agrawal, N. R., Suppiah, R., Hsi, E. D., Andresen, S. W., Karam, M. A., Reed, J., Faiman, B. M., et al. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.7.889 · Cited by 108
Gold Nanoparticles Inhibit the Proliferation of Multiple Myeloma Cells
Bhattacharya, R., Patra, C. R., Verma, R., Kumar, S. K., Greipp, P. R., & Mukherjee, P. (2007) · Advanced Materials · doi:10.1002/adma.200602098 · Cited by 106
Corre, J., Labat, E., Espagnolle, N., Hébraud, B., Avet-Loiseau, H., Roussel, M., Huynh, A., Gadelorge, M., Cordelier, P., Klein, B., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-0188 · Cited by 103
“The disease is fatal and the median survival is 5 years (2), but this survival has significantly increased with the introduction of novel therapies, (3) with some patients surviving more than 10 years (4).”
BackgroundSelf-citationHarousseau, J.-L., Palumbo, A., Richardson, P. G., Schlag, R., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Kentos, A., Cavo, M., Golenkov, A., et al. (2010) · Blood · doi:10.1182/blood-2010-03-275800 · Cited by 105
Self-citationPerspectives in treatment of AL amyloidosis
Wechalekar, A. D., Hawkins, P. N., & Gillmore, J. D. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06936.x · Cited by 105
“Patients with myeloma who do not achieve a complete or very good partial response after ASCT may benefit from a second ASCT (Attal et al, 2003), and using a similar rationale, this tandem approach achieved a remarkable 67% complete response rate in a study in AL amyloidosis (Sanchorawala et al,…”
MethodRotta, M., Storer, B. E., Sahebi, F., Shizuru, J. A., Bruno, B., Lange, T., Agura, E. D., McSweeney, P. A., Pulsipher, M. A., Hari, P., et al. (2008) · Blood · doi:10.1182/blood-2008-07-170746 · Cited by 108
“VGPR 19 CR 6 CR 6 2 (25, 77) 2 (3, 7) 2 (55, 89) VGPR 13 CR 13 6 (median 26, range 16-38) 1 (47) 6 (median 47, range 30-83) PR 50 CR 4 CR 4 2 (11, 11) 2 (47, 85) VGPR 10 CR 6 2 (14, 16) 4 (median 81, range 35-102) VGPR 4 2 (56, 66) 2 (5,77) PR 36 PR 14 7 (median 17, range 1-48) 5 (median 7, range 3-13) 2 (33, 49) VGPR…”
Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells
Dingli, D., Chalub, F. A. C. C., Santos, F. C., Segbroeck, S. V., & Pacheco, J. M. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605288 · Cited by 115
“This is supported by ample clinical data, whereby high-dose chemotherapy and stem cell transplantation lead to significant reductions in tumour burden with an improvement in survival but the disease invariably relapses (Attal et al, 1996, 2003).”
BackgroundResultHaessler, J., Shaughnessy, J. D., Zhan, F., Crowley, J., Epstein, J., van Rhee, F., Anaissie, E., Pineda-Roman, M., Zangari, M., Hollmig, K., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0527 · Cited by 101
How we manage autologous stem cell transplantation for patients with multiple myeloma
Gertz, M. A., & Dingli, D. (2014) · Blood · doi:10.1182/blood-2014-03-544759 · Cited by 106
Kumar, A., Kharfan‐Dabaja, M. A., Glasmacher, A. G., & Djulbegović, B. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn439 · Cited by 112
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma
Olin, R. L., Vogl, D. T., Porter, D., Luger, S. M., Schuster, S. J., Tsai, D. E., Siegel, D. L., Cook, R. J., Mangan, P. A., Cunningham, K., et al. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.334 · Cited by 100
Impact of early relapse after auto-SCT for multiple myeloma
Kumar, S. K., Mahmood, S., Lacy, M. Q., Dispenzieri, A. A., Hayman, S. R., Buadi, F. K., Dingli, D., Rajkumar, S. V., Litzow, M. R., & Gertz, M. A. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.180 · Cited by 102
“40 The benefit of a tandem approach in this group of patients were not specifically addressed, but several randomized trials have shown an event free and overall survival benefit for tandem approaches in patients failing to achieve a very good partial response to the first autograft”
BackgroundNeurological toxicity of long‐term (>1 yr) thalidomide therapy in patients with multiple myeloma
Tosi, P., Zamagni, E., Cellini, C., Plasmati, R., Cangini, D., Tacchetti, P., Perrone, G., Pastorelli, F., Tura, S., Baccarani, M., et al. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00382.x · Cited by 98
Mehta, J. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp320 · Cited by 98
Palumbo, A., Bringhen, S., Bruno, B., Falcone, A. P., Liberati, A. M., Grasso, M., Ria, R., Pisani, F., Cangialosi, C., Caravita, T., et al. (2009) · Blood · doi:10.1182/blood-2009-09-241737 · Cited by 105
Uses and Growth of Hematopoietic Cell Transplantation
Horowitz, M. M. (2015) · Wiley eBooks · doi:10.1002/9781118416426.ch2 · Cited by 101
Bruno, B., Rotta, M., Patriarca, F. F., Mattei, D. G., Allione, B., Carnevale‐Schianca, F., Sorasio, R., Rambaldi, A., Casini, M., Parma, M., et al. (2008) · Blood · doi:10.1182/blood-2008-07-167379 · Cited by 100
Sundaresan, N., Boriani, S., Rothman, A., & Holtzman, R. N. N. (2004) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000041888.33499.03 · Cited by 96
Knop, S. T., Straka, C., Haen, M., Schwedes, R., Hebart, H. F., & Einsele, H. (2005) · PubMed · Cited by 99
Multiple Myeloma in the Older Adult: Better Prospects, More Challenges
Wildes, T. M., Rosko, A. E., & Tuchman, S. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.1028 · Cited by 98
“than age 65 years; however, adults older than age 65 years were categorically excluded from these pivotal studies.(31,32)Over the past two decades, ASCT has been increasingly used in older adults; from 1995 to 2005, the proportion of individuals older than age 70 years undergoing ASCT increased more than five-fold, fr…”
BackgroundMoreau, P., Hulin, C., Garban, F., Yakoub‐Agha, I., Benboubker, L., Attal, M., Marit, G., Fuzibet, J., Doyen, C., Voillat, L., et al. (2005) · Blood · doi:10.1182/blood-2005-06-2573 · Cited by 101
“t(4;14), yes/no/missing 26/116/77 10/47/28 10/58/13 1”
BackgroundResultInfluentialSelf-citationKumar, S. K., Dispenzieri, A., Fraser, R., Mingwei, F., Akpek, G., Cornell, R., Kharfan-Dabaja, M., Freytes, C., Hashmi, S., Hildebrandt, G., et al. (2018) · Leukemia · doi:10.1038/leu.2017.331 · Cited by 92
“56) Disease status at transplant CR 142 (12) 140 (14) 171 (19) PR 860 (74) 760 (77) 652 (73) MR/NR/SD 108 (9) 67 (7) 56 (6) Relapse/Progression 45 (4) 16 (2) 14 (2) Unknown 1 (<1) 1 (<1) 0 Sensitivity to chemotherapy Sensitive 1002 (87) 900 (91) 823 (92) Resistant 153 (13) 83 (8) 70 (8) Unknown 1 (<1) 1 (<1) 0 Time fr…”
Dingli, D., Nowakowski, G. S., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Litzow, M. R., Gastineau, D. A., & Gertz, M. A. (2006) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2006.n.014 · Cited by 92
D’Addio, A., Curti, A., Worel, N., Douglas, K., Motta, M. R., Rizzi, S., Dan, E., Taioli, S., Giudice, V., Agis, H., et al. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.128 · Cited by 88
Chang, H., Trieu, Y., Qi, X., Xu, W., Stewart, K., & Reece, D. E. (2006) · Leukemia Research · doi:10.1016/j.leukres.2006.08.002 · Cited by 91
Martin, P. J., Bachier, C. R., Klingemann, H.-G., McCarthy, P. L., Szabolcs, P., Uberti, J. P., Schuster, M. W., Weisdorf, D. J., Chao, N. J. A., Kebriaei, P., et al. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.03.012 · Cited by 94
Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation
Sharma, M. R., Zhang, M., Zhong, X., Abidi, M. H., Akpek, G., Bacher, U., Callander, N. S., Dispenzieri, A. A., Freytes, C. O., Fung, H. C. H., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.07.013 · Cited by 84
“Randomized studies confirm the benefit of autologous transplantation in subjects 65 years of age, but these studies typically excluded older subjects [4,5].”
AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome
Wechalekar, A. D., Lachmann, H. J., Goodman, H. J. B., Bradwell, A. R., Hawkins, P. N., & Gillmore, J. D. (2008) · Blood · doi:10.1182/blood-2008-02-138156 · Cited by 83
“Liver, consensus criteria 15 (14) Liver, SAP scintigraphy 39 (38) Renal, consensus criteria 55 (53) Renal, SAP scintigraphy 49 (47) Cardiac, any involvement 36 ( 35 ) Cardiac, IVS 15 mm or more 4 (3) Lymph nodes 22 (21) Peripheral neuropathy 4 (3) Autonomic neuropathy 8 (7) Soft tissue 14 (13) Gastrointestinal tract 5…”
BackgroundInfluentialSteidl, U. G., Fenk, R. R., Bruns, I., Neumann, F., Kondakci, M., Hoyer, B., Graef, T. T., Rohr, U.-P., Bork, S., Kronenwett, R., et al. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704702 · Cited by 88
Sonneveld, P., van der Holt, B., Segeren, C. M., Vellenga, E., Croockewit, A. J., Verhoef, G., Cornelissen, J. J., Schaafsma, M. R., van Oers, M. H. J., Wijermans, P., et al. (2007) · Haematologica · doi:10.3324/haematol.11168 · Cited by 87
“The French IFM group showed, in a randomized trial, that double high-dose treatment followed by autologous SCT improves the PFS in patients who do not achieve a very good partial response or complete response with one intensive treatment.(9) In addition, the Bologna study also showed superior CR, EFS and OS rates alth…”
InfluentialHarousseau, J., Shaughnessy, J. D., & Richardson, P. G. G. (2004) · Hematology · doi:10.1182/asheducation-2004.1.237 · Cited by 106
Self-citationBakkus, M. H. C., Bouko, Y., Samson, D., Apperley, J. F., Thielemans, K., Camp, B. V., Benner, A., Goldschmidt, H., Moos, M., & Cremer, F. W. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05120.x · Cited by 81
“The number of HDT cycles was included in our proportional hazards model, as the update of the Intergroupe Français du Myelome (IFM) trial (IFM-95) demonstrated a superior outcome for patients treated by sequential HDT (Attal et al, 2003).”
BackgroundMethodBarosi, G., Boccadoro, M., Cavo, M., Corradini, P., Marchetti, M., Massaia, M., Merlini, G., Tosi, P., & Tura, S. (2004) · PubMed · Cited by 88
Dingli, D., Nowakowski, G. S., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Rajkumar, S. V., Greipp, P. R., Litzow, M. R., Gastineau, D. A., Witzig, T. E., et al. (2005) · Blood · doi:10.1182/blood-2005-08-3398 · Cited by 85
“Panels B and C represent patients with a few (5) or many (1080) CMCs, respectively.”
BackgroundLongitudinal Analysis and Prognostic Effect of Cancer-Testis Antigen Expression in Multiple Myeloma
Atanackovic, D., Luetkens, T., Hildebrandt, Y., Arfsten, J., Bartels, K., Horn, C., Stahl, T., Cao, Y., Zander, A. R., Bokemeyer, C., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0989 · Cited by 81
Avet-Loiseau, H. (2010) · Hematology · doi:10.1182/asheducation-2010.1.489 · Cited by 77
Zeiser, R., Deschler-Baier, B., Bertz, H., Finke, J., & Engelhardt, M. M. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704713 · Cited by 81
Rajkumar, S. V., Richardson, P. G., Lacy, M. Q., Dispenzieri, A., Greipp, P. R., Witzig, T. E., Schlossman, R., Sidor, C. F., Anderson, K. C., & Gertz, M. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0807 · Cited by 75
“However, despite the use of conventional chemotherapy (3), autologous stem cell transplantation (4, 5), and newer highly effective agents including thalidomide, bortezomib, and lenalidomide (6–11), most patients still relapse and succumb to their myeloma.”
BackgroundCurrent approaches to management of newly diagnosed multiple myeloma
Goel, U., Usmani, S. Z., & Kumar, S. K. (2022) · American Journal of Hematology · doi:10.1002/ajh.26512 · Cited by 82
“The early ASCT arm received vincristine, Adriamycin, melphalan, and prednisolone (VAMP) followed by ASCT.”
ResultInfluentialBlanes, M., Lahuerta, J. J., González, J. D., Ribas, P., Solano, C., Alegre, A. M., Bladé, J., Miguel, J. F. S., Sanz, M. Á., & de la Rubia, J. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.08.009 · Cited by 78
Kovacs, M. J., Reece, D. E., Marcellus, D. C., Meyer, R. M., Mathews, S., Dong, R.-P., & Eisenhauer, E. A. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-9022-7 · Cited by 77
Barlogie, B., Tricot, G. J. K., Haessler, J., van Rhee, F., Cottler‐Fox, M., Anaissie, E. J., Waldron, J. A., Pineda‐Roman, M., Thertulien, R., Zangari, M., et al. (2007) · Blood · doi:10.1182/blood-2007-06-097444 · Cited by 78
“One del(20q) 25 (24) 7/7q 16 (15) t(1;7)(q10;p10) 14 (13) 5/5q 10 (10) del(13q) 7 (7) 8 5 (5) del(11q) 2 (2) del(16q) 1 (1) t(3;21) 1 (1) Inv(3) 1 (1) der(1;14)(q10;q10) 0 (0) del(12p) 0 (0) Two 7/7q , 5/5q 6 (6) t(1;7)(q10;p10), 8 3 (3) 7/7q , del(20q) 3 (3)”
BackgroundMultiple Myeloma, Version 2.2016
Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C. L., Djulbegović, B., Fung, H. C. H., Gasparetto, C., Godby, K. N., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0167 · Cited by 85
Němec, P., Zemanová, Z., Grešlíková, H., Michalova, K., Filková, H., Tajtlová, J., Kralova, D., Kupská, R., Smetana, J., Krejčí, M., et al. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.11.025 · Cited by 79
“High-dose chemotherapy with autologous stem cell transplantation (SCT) has become the standard of care for all eligible MM patients, and has been shown to prolong survival [1,2].”
BackgroundArmeson, K. E., Hill, E. G., & Costa, L. J. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.173 · Cited by 74
Rajkumar, S. V. (2009) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2009.01.001 · Cited by 94
Nademanee, A. P., DiPersio, J. F., Maziarz, R. T., Stadtmauer, E. A., Micallef, I. N., Stiff, P. J., Hsu, F. J., Bridger, G. J., & Bolwell, B. J. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.05.017 · Cited by 70
Lee, S. J., Richardson, P. G. G., Sonneveld, P., Schuster, M. W., Irwin, D. H., Miguel, J. F. S., Crawford, B., Massaro, J. M., Dhawan, R., Gupta, S. K., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07378.x · Cited by 72
“It is incurable and follows a relapsing course, with a median survival of approximately 4–5 years (Attal et al, 2003; Barlogie et al, 2006; Facon et al, 2007; Hulin et al, 2007; Kumar et al, 2008).”
BackgroundBadr, G., Mohany, M., & Abu-Tarboush, F. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-236 · Cited by 68
“Clinically, it is characterized by high levels of paraproteins in the blood and/or urine, lytic bone lesions, anemia, renal dysfunction, and bone marrow (BM) plasmacytosis [2].”
BackgroundDerlin, T., Weber, C., Habermann, C. R., Herrmann, J., Wisotzki, C., Ayuk, F. A., Wolschke, C., Klutmann, S., & Kröger, N. M. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1993-8 · Cited by 70
“thalidomide, lenalidomide and bortezomib) for induction and maintenance combined with a single or tandem autologous haematopoietic stem cell transplantation (SCT)—may result in significantly prolonged overall survival, and survival beyond 10 years is not uncommon now [3, 4].”
BackgroundReduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma
de Lavallade, H., Cheikh, J. E., Faucher, C., Fürst, S., Am, S., Coso, D., Bouabdallah, R., Chabannon, C., Gastaut, J. A., Blaise, D., et al. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.22 · Cited by 69
Self-citationMai, E. K., Benner, A., Bertsch, U., Brossart, P., Hänel, A., Kunzmann, V., Naumann, R., Neben, K., Egerer, G., Ho, A. D., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13994 · Cited by 73
Bruns, I., Steidl, U. G., Kronenwett, R., Fenk, R. R., Graef, T. T., Rohr, U., Neumann, F., Fischer, J., Scheid, C., Hübel, K., et al. (2005) · Transfusion · doi:10.1111/j.1537-2995.2006.00699.x · Cited by 69
“9) Number of applications† 1 1 11 (8-15) First day of cytokine application 4 (2-9) 4 (3-6) 4 (2-7) Number of days to WBC reconstitution to >1 × 10(9)/L‡ 12 (8-16) 12 (7-14) 14 (11-15)”
Mohty, M., & Harousseau, J. (2014) · Haematologica · doi:10.3324/haematol.2013.096149 · Cited by 70
“, double ASCT resulted in an OS benefit in patients who did not achieve a VGPR after the first transplant.(60) In a recently published Cochrane Database systematic review of first-line tandem ASCT versus single HDT/ASCT studies, the authors concluded that none of”
BackgroundSelf-citationLenhoff, S., Hjorth, M., Turesson, I., Westin, J., Gimsing, P., Wislöff, F., Ahlberg, L., Carlson, K. E., Christiansen, I., Dahl, I. M. S., et al. (2006) · PubMed · Cited by 72
Pineda‐Roman, M., Bolejack, V., Arzoumanian, V., Anaissie, E., Van Rhee, F., Zangari, M., Walker, R., Hollmig, K., Shaughnessy, J. D., Epstein, J., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06441.x · Cited by 66
“…has been extended beyond 6 years, presumably as a result of profound tumour cytoreduction (Barlogie et al, 1999) reflected by complete response (CR) rates of 20% with single and 40% with tandem transplants (Attal et al, 1996; Attal et al, 2003; Child et al, 2003; Barlogie et al, 2005, 2006).”
BackgroundEpidemiology and outcomes research for MGUS, myeloma and amyloidosis
Sirohi, B., & Powles, R. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.065 · Cited by 72
Mesenchymal Stem Cell Therapy of Pulmonary Fibrosis: Improvement with Target Combination
Chuang, H.-M., Shih, T. E., Lu, K.-Y., Tsai, S.-F., Harn, H., & Ho, L. (2018) · Cell Transplantation · doi:10.1177/0963689718787501 · Cited by 66
Protein Transduction of Dendritic Cells for NY-ESO-1-Based Immunotherapy of Myeloma
Batchu, R. B., Moreno, A., Szmania, S. M., Bennett, G., Spagnoli, G. C., Ponnazhagan, S., Barlogie, B., Tricot, G. J. K., & van Rhee, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1383 · Cited by 69
“Autologous blood stem cell–supported high-dose melphalan therapy has emerged as the treatment of choice for the primary care of younger patients with multiple myeloma (1, 2).”
BackgroundMahtouk, K., Moreaux, J., Hose, D., Reme, T. X., Meißner, T., Jourdan, M., Rossi, J. F., Pals, S. T., Goldschmidt, H., & Klein, B. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-198 · Cited by 70
“It is still an incurable disease with an average 5-year survival after high dose chemotherapy and autologous stem cells transplantation [1].”
Vesole, D. H., Pérez, W. S., Akasheh, M., Boudreau, C., Reece, D. E., & Bredeson, C. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.7.880 · Cited by 64
“of patients 107 Median age of patients (y) (range) 55 (31-71) Male 64 (60) Pretransplantation Karnofsky score (n=101) <80 23 (23) 80 42 (42) >80 36 (36) Median serum monoclonal immunoglobulin, g/dL (range) (n=31) 0.”
InfluentialMultiple myeloma – an update on diagnosis and treatment
Caers, J., Broek, I. V., Raeve, H. D., Michaux, L., Trullemans, F., Schots, R., Camp, B. V., & Vanderkerken, K. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01127.x · Cited by 75
“single transplantation in patients who obtained only a PR after first transplant (66).”
BackgroundBataille, R., Pellat‐Deceunynck, C., Robillard, N., Avet‐Loiseau, H., Harousseau, J., & Moreau, P. (2007) · Leukemia Research · doi:10.1016/j.leukres.2007.07.016 · Cited by 68
Self-citationHundemer, M., Schmidt, S., Condomines, M., Lupu, A., Hose, D., Moos, M., Cremer, F. W., Kleist, C., Terness, P., Belle, S., et al. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.01.008 · Cited by 63
“With high-dosed alkylating drugs followed by autologous stem cell transplantation, complete remission can be achieved in 40% of patients [1,2].”
BackgroundProlonged overall survival with second on-demand autologous transplant in multiple myeloma
Elice, F., Raimondi, R., Tosetto, A., D’Emilio, A., Bona, E. D., Piccin, A., & Rodeghiero, F. (2006) · American Journal of Hematology · doi:10.1002/ajh.20641 · Cited by 63
“4 months) is similar to that reported in the tandem arm of the IFM trial (58 months) and in the Total Therapy program (68 months), despite less favorable results in terms of CR rate and EFS [17,24].”
BackgroundResultHigh-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease
Hassoun, H., Flombaum, C. D., D’Agati, V. D., Rafferty, B. T., Cohen, A. D., Klimek, V. M., Boruchov, A. M., Kewalramani, T., REICH, L. M., Nimer, S. D., et al. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.179 · Cited by 62
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Harousseau, J., & Dreyling, M. H. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq178 · Cited by 76
Self-citationSive, J. I., Cuthill, K., Hunter, H. M., Kazmi, M. A., Pratt, G., Smith, D., & British Society of Haematology (2021) · British Journal of Haematology · doi:10.1111/bjh.17410 · Cited by 69
“However, subgroup analyses in two of the historical studies demonstrated an improved PFS and OS for those patients who did not reach at least a VGPR with the first transplant.(142,143) Two more recent RCTs show differing results.”
ResultBannas, P., Hentschel, H., Bley, T. A., Treszl, A., zu Eulenburg, C., Derlin, T., Yamamura, J., Adam, G., Stübig, T., Kröger, N. M., et al. (2012) · European Radiology · doi:10.1007/s00330-012-2445-y · Cited by 63
“Survival beyond 10 years is not uncommon today [8, 9].”
BackgroundCarfilzomib: A second-generation proteasome inhibitor for the treatment of multiple myeloma
McBride, A., Klaus, J., & Stockerl-Goldstein, K. E. (2015) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp130281 · Cited by 67
Somlo, G., Spielberger, R. T., Frankel, P. H., Karanes, C., Krishnan, A. Y., Parker, P. M., Popplewell, L. L., Sahebi, F., Kogut, N. M., Snyder, D., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1912 · Cited by 64
“Single and tandem autologous stem cell transplantation (TASCT) have improved CR and VGPR rates, leading to improved progressionfree (PFS) and overall survival (OS) (4-6).”
BackgroundInfluentialLack of CD27 in myeloma delineates different presentation and outcome
Moreau, P., Robillard, N., Jégo, G., Pellat‐Deceunynck, C., Gouill, S. L., Thoumi, S., Avet‐Loiseau, H., Harousseau, J., & Bataille, R. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05849.x · Cited by 67
“Diagnostic criteria and treatment regimens have already been published (Attal et al, 1996, 2003).”
BackgroundSelf-citationKim, J. S., Kım, K., Cheong, J., Min, Y. H., Suh, C., Kim, H., Jo, D. Y., Ryoo, H. M., Yoon, S. S., & Lee, J. H. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.12.512 · Cited by 62
Metadata
- Authors
- Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., Voillat, L., Sotto, J.-J., Grosbois, B., & Bataille, R.
- Affiliations
- Hôpital Purpan (FR)
- Hôpital Claude Huriez (FR)
- Centre Hospitalier Universitaire de Poitiers (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Centre Henri Becquerel (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- CHU Dijon Bourgogne (FR)
- Centre Hospitalier Universitaire de Besançon (FR)
- Hôpital Albert Michallon (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-12-25
- Volume
- 349
- Issue
- 26
- Pages
- 2495-2502
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1982499121
- Cited by
- 984
- References
- 16
- Citations by year
- 2026: 3 · 2025: 13 · 2024: 18 · 2023: 14 · 2022: 22 · 2021: 20 · 2020: 33 · 2019: 18 · 2018: 35 · 2017: 28 · 2016: 24 · 2015: 37 · 2014: 38 · 2013: 53 · 2012: 42
- FWCI
- 34.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, autologous stem cell transplantation, high-dose chemotherapy, overall survival, event-free survival, very good partial response, beta2-microglobulin, lactate dehydrogenase, prognostic factors
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Dexamethasone, Doxorubicin, Female, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm Staging, Prognosis, Transplantation, Autologous, Vincristine, Survival Rate, Multivariate Analysis, Hematopoietic Stem Cell Transplantation, Disease-Free Survival, Transplantation Conditioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.